TriNetX Expands Genomics Data Capabilities via Zetta Genomics Acquisition

TriNetX Enhances Genomic Data Integration

TriNetX, a leader in health data networks, has made significant strides in genomic data management through the acquisition of key assets from Zetta Genomics. This strategic move is set to bolster TriNetX's global capabilities in genomic data collection and analysis, enhancing its partnerships and healthcare provider network around the world.

The acquisition, announced on April 7, 2026, marks a pivotal moment for TriNetX as it seeks to grow its portfolio in the realm of multi-omics data. Zetta Genomics, known for its flagship platform, XetaBase, specializes in the collection and analysis of multi-omics data, a vital component for advancing genomic research at the population level. The integration of XetaBase into TriNetX's ecosystem will enable healthcare providers to offer improved patient care by analyzing complex genomic data alongside phenotypic information.

Before this acquisition, TriNetX and Zetta Genomics have demonstrated a strong collaborative relationship that dates back to 2024, illustrating their effectiveness in federated querying of secure genomic data. Through extensive technical feasibility studies, both entities ensured that they could provide cohesive and insightful analyses that further enhance clinical research and practice outcomes.

Jeff Margolis, Executive Chairman of TriNetX, expressed his enthusiasm over the integration, highlighting the solid partnership established through personnel such as COO Steve Kundrot. The combined strengths of both companies exemplify a progressive direction towards data-driven healthcare solutions. The acquisition is also reflective of TriNetX's commitment to promoting multi-omics research, ensuring that healthcare providers are equipped with localized data solutions to upscale their infrastructures effectively.

In agreement, Jeffrey Brown, PhD, Chief Scientific Officer at TriNetX, emphasized that the ultimate goal of improving human health through data is now further enhanced with the addition of the XetaBase technology. He recognized that integrating different types of data is essential for both clinical advancements and scientific progress.

Ignacio Medina Castello, CEO and Chief Technology Officer of Zetta Genomics, conveyed pride in Zetta's achievements and the future possibilities within the TriNetX framework. He noted that the merger would escalate their work, allowing them to encompass a broader global community of healthcare partners and research initiatives.

As one of the pivotal health data networks globally, TriNetX aims to connect healthcare institutions, researchers, and industry stakeholders with real patient data insights. With contributions from more than 11,000 healthcare providers across 20 countries, TriNetX prioritizes accuracy, privacy, and trust in handling health data.

Through this new acquisition, TriNetX is positioned to redefine how genomic data facilitates patient care and research. With Zetta's innovative technology at its disposal, TriNetX continues to lay down a robust foundation for future healthcare solutions that are tailored to navigate the complex landscape of genomics.

In conclusion, the acquisition fortifies a shared vision between TriNetX and Zetta Genomics to push the boundaries of genomic research and enhance the quality of healthcare provided. Stakeholders can expect significant advancements as both companies work in unison to unlock the potential of genomic data applications across their global networks.